-+ 0.00%
-+ 0.00%
-+ 0.00%

RHYTHM PHARMACEUTICALS TO ANNOUNCE TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRANSCEND TRIAL EVALUATING SETMELANOTIDE IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY

Reuters·04/06/2025 16:00:02

Please log in to view news